Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer

Overview of attention for article published in JAMA Oncology, February 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 1 news outlet
policy: 2 policy sources
twitter: 31 X users

facebook: 1 Facebook page
googleplus: 1 Google+ user

Readers on

mendeley: 85 Mendeley

So far, Altmetric has seen 2 policy documents that reference this research output.

Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence (NICE) on 21 Aug 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Comments To CMS On Proposed International Pricing Index for Medicare Part B Drugs

Cited by American Action Forum on 07 Jan 2019

The American Action Forum (AAF), led by former Director of the Congressional Budget Office Douglas Holtz-Eakin, proudly leads the center-right on economic, domestic, and fiscal policy issues.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.